Greetings, and welcome to the Celyad Oncology first half 2022 financial results. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Sara Zelkovic, Director of Communications and Investor Relations for Celyad Oncology. Thank you. You may begin. Thank you all for joining us today. Before we begin, I would like to remind everyone that today's event may contain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks and uncertainties, which might cause actual results, financial condition, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. A list and description of these risks, uncertainties, and other risks can be found in the company's U.S. Securities and Exchange Commission filings and reports, including in its annual report on Form 20-F filed with the SEC on March 24, 2022, and subsequent filings and reports by the company. These forward-looking statements speak only as of the date of this call, and the company's actual results may differ materially from those expressed or implied by these forward-looking statements. The company expressly disclaims any obligation to update any such forward-looking statements made on this call to reflect any change in its expectations with regard thereto or any change in events, conditions, or circumstances on which any such statement is based, unless required by law or regulation. Let me now turn the call over to Michel Lussier, Interim Chief Executive Officer of Celyad Oncology. Michel, the floor is yours. Thank you, Sarah, and thank you everyone for joining us today for our financial results and operational results update call for the first half of 2022. Joining me today from the executive committee team is our Chief Medical Officer, Dr. Charlie Morris, and our Vice President of Finance and Administration, David Georges. We will start today with an operational and clinical update, followed by an overview of the financials and outlining the expected key milestones of the company over the next several months. We will then open the line for your questions. There has been many changes to the company in terms of the clinical candidates and leadership in the first half of the year. Importantly, we say goodbye to our previous CEO, Filippo Petti, who stepped down in June to seek other opportunities. I must say we've had a very smooth transition over the past month, and I've taken over as Interim CEO. I want to thank dearly Filippo for his broad contributions to Celyad Oncology over the past years. We have begun the search for a new CEO and are targeting a European-based person to helm our headquarters in Belgium. We're also happy to announce that the Board of Directors has named Hilde Windels. Hilde has been on our Board for a number of years and will now be the chair of our Board of Directors because I stepped down as Chairman to take the CEO helm. She's a prominent Board Member in the European biotech industry, and we look forward to continuing our work under her guidance. In addition, Dr. David Gilham, our former Chief Scientific Officer, also resigned to seek other opportunities. David has been with the company almost eight years, and he felt this timing was a natural transition as the new Head of R&D, Dr. Eytan Breman, takes over to continue our work on our shRNA platform and discovery CAR-T programs. I also thank David for his significant reshaping of our R&D efforts as we shifted our approach in the field of CAR-T towards allogeneic therapies underpinned by shRNA technology. While we've had many changes in the past few months, we look forward to focusing our efforts on four major pillars of the business to maximize all potential value drivers of the company in the coming months and years. Our first pillar is our Research and Development efforts. A main focus will be on research that will utilize our shARC or shRNA armored CAR-T franchise. We introduced this platform last year. Although we did make the decision in April to stop development of CYAD-203, our allogeneic shRNA-based IL-18 armored NKG2D CAR-T candidate, I want to note that we're making promising progress in multiple discovery programs focused on the co-expression of IL-18, including the exploration of backup allogeneic NKG2D receptor CAR-T candidates which leverage this platform. Currently, our armored CAR-Ts are engineered to release IL-18, providing the opportunity to drive increased potency of our cell therapy by impacting the CAR-T and the local tumor microenvironment, especially important for the treatment of solid tumors. We think that this is an ideal platform for developing unique CAR-T products for difficult to treat diseases and could overcome the challenges related to treating solid tumors. Moving to our pipeline, our next pillar, we've had challenges and opportunities related to our allogeneic CAR-T candidates this year and are happy to announce that our trials are getting back on track where they should be. At the end of July, we received notification from the FDA that they are lifting the clinical hold put on our investigational candidate, CYAD-101. This is a significant milestone for the company, and we're very excited at the potential development of CYAD-101 and other product candidates using our TIM technology. Patient safety continues to be our biggest priority, and we're proud to have safely tested many people with cancer using our TIM technology and NKG2D targeting CARs in clinical trials. I'd like to take this time to thank the team for their hard work and dedication to providing timely responses to the FDA in order to get this hold lifted as quickly as possible. In addition, enrollment for the dose escalation portion of IMMUNICY-1 trial with CYAD-211 has been steady with one patient enrolled per month, and we're excited about the data we're generating and will share this year. IMMUNICY-1 has been an invaluable way for us to showcase the benefits of our proprietary shRNA technology in a real-world clinical setting. We truly believe that this non-gene editing technology offers great opportunity to drive differentiated candidates for both solid tumors and hematological malignancies. The third pillar and a value driver has been our underutilized so far in the company relates to our unique intellectual property within the CAR-T landscape. Our U.S. patents around allogeneic CAR-T therapy and NKG2D-based therapies provide an avenue for the company to develop its own program and to partner with outside parties around the licensing of these patents. We are planning a renewed strategic focus to leverage additional potential licenses. Finally, the last pillar of a renewed strategy as we see a significant opportunity is our in-house manufacturing expertise. This facility has been a great investment for us over the past decade, and we are currently evaluating opportunities on how we can further leverage this core asset within the overall strategy of our business. Let me stop here and turn the call over to Dr. Charlie Morris, our Chief Medical Officer, to provide more detail. Charlie? Thank you, Michel, and thank you everyone again for joining us today. As Michel just discussed, we have several updates related to our pipeline in the first part of 2022. Let's first turn to CYAD-101, Celyad's first-in-class non-gene edited clinical candidate that co-expresses the NKG2D receptor and the novel TCR inhibitory molecule or TIM, which interferes with native CD3 zeta, I'm sorry, reducing the signaling of the TCR complex. Of note, CYAD-101 is the only investigational candidate from the company using the TIM technology. We completed our previous CYAD-101 trial called alloSHRINK last year, and in December 2021 began the CYAD-101-002, otherwise known as KEYNOTE-B79 clinical trial. This phase I-B trial is evaluating CYAD-101, followed by Merck's anti-PD-1 therapy, Keytruda, in refractory metastatic colorectal patients with microsatellite stable mismatch repair- proficient disease, a difficult indication for immunotherapies to date. As Michel just mentioned, the FDA has lifted the clinical hold previously put on this trial. The amendments that we suggested that were accepted by the FDA state that we will exclude patients with bilateral lung metastases and prior history of anti-EGFR antibodies within nine months of recruitment to the trial. We are continuing to evaluate the use of NKG2D receptors in our research, along with our unique proprietary non-gene edited technologies. Our second phase I trial evaluates CYAD-211, a potential first-in-class allogeneic CAR-T candidate engineered to co-express a BCMA-targeting CAR and a single shRNA, which interferes with the expression of the CD3 zeta component of the TCR complex. CYAD-211 is currently in the dose escalation portion of the phase I IMMUNICY-1 trial, which is evaluating the tolerability and clinical activity of a single infusion of CYAD-211 following preconditioning with cyclophosphamide and fludarabine, known as CyFlu, in patients with relapsed and refractory multiple myeloma. Initial data from IMMUNICY-1 showed all patients had detectable CYAD-211 cells in the peripheral blood, although engraftment to date has been short-lasting. These findings suggest that deeper and more durable lymphodepletion may maximize engraftment and persistence of the cells. Our current segment of IMMUNICY-1 follows an enhanced lymphodepletion regimen with the aim of improving cell expansion and persistence and to potentially maximize the clinical activity of CYAD-211. In addition, we are also evaluating increased dose of CYAD-211 within the IMMUNICY-1 protocol, which might help drive additional clinically beneficial responses. For this trial, we plan to share additional clinical data during the second half of 2022. We truly feel that our technologies offer potential benefits over other approaches in the space, and help us to lead the way in developing innovative allogeneic therapies for the treatment of cancer. We've made great progress, particularly with our shRNA technology in previous and current clinical candidates. We have continued to expand our research efforts into how to best leverage the dynamic potential of the shRNA platform, including multiplexing and targeting immune evasion, and its potential to serve as a backbone for armored CARs using our proprietary shARC franchise. With that, let me turn the call to our VP of Finance, David Georges. Thank you, Charlie. Turning to our financials, I would just like to remind you all that our full financial details are available on the Celyad Oncology website in both French and English language. Our research and development expenses were EUR 10.5 million for the first half of 2022, compared to EUR 10 million for the first half of 2021. The half million EUR increase was mainly driven by intellectual property filing and maintenance fees to strengthen intellectual property prosecution, and also by the increase of employees' expenses related to movement of employees through the year 2021 and 2022 to support the group's pre-clinical and clinical programs. This increase has been partly compensated by the decrease of clinical activities, mainly due to the phase I-B CYAD-101-002, KEYNOTE-B79 trial, which was on clinical hold during the second quarter of 2022. General and administrative expenses were EUR 6.2 million for the first half of 2022, compared to EUR 4.8 million for the first half of 2021. The increase was associated with an increase in insurance costs, combined with the increase of employee expenses, mainly related to movement of employees through the six-month period ended June 30, 2022. Net other income for the first half of 2022 was EUR 1.6 million, compared to a net other income of EUR 1.8 million for the first half of 2021. Our net other income for the first half of 2022 was associated with grant received from the Walloon region for EUR 1.4 million. Net loss for the first half of 2022 was EUR 14.1 million, or EUR 0.62 per share, compared to a net loss of EUR 14.9 million, or EUR 1.02 per share for the same period in 2021. Net cash used in the operations amounted to EUR 16.3 million for the first half of 2022, as compared with EUR 12.2 million for the first half of 2021. As of June 30, 2022, the company had a treasury position of approximately EUR 14.4 million or $15 million. As of June 30, 2022, the total number of basic shares outstanding were 22.6 million, which is similar to the situation of December 31, 2021. With that, I will now turn the call back to Michel for closing statements. Thank you, David. In closing, we're looking forward to this renewed sense of focus and strategy for Celyad Oncology. As mentioned previously, we will be exploring four main pillars of strategy to further leverage all possible value drivers for the company. These include examining the way we're using our manufacturing expertise, our intellectual property portfolio, our clinical pipeline candidates, and our current R&D endeavors. We hope to provide additional thoughts on these topics over the coming months and year as we execute on these strategies. We look forward to reporting additional data for the CYAD-211 IMMUNICY-1 phase I trial by the end of the year, and make additional announcements regarding our clinical program as a whole over the coming months. With that, I'll turn the call over for your questions. Operator? Thank you. At this time, we'll be conducting a question and answer session. If you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question comes from the line of Raju Prasad with William Blair. Please proceed with your question. Thanks for taking the question. Curious to know the reasoning behind the nine months lead-in on EGFR therapies as an exclusion criteria for taking up the clinical hold? Thanks. Hi, Raju. Yeah. Both of the patients who had a history of exposure to anti-EGFR, one around about six months away. We felt having seen that, we should. You know, use six months as, if you like, as a baseline, 'cause obviously we had other patients who had been treated within six months who had not had severe adverse effects. If we take six months as a baseline and then a conservative sort of washout time, 5 half-lives of cetuximab, for example, takes you out to about 10 weeks, so you're then out to about 9 months. Okay, great. You know, you mentioned a little bit around business development strategy and IP. Can you give us a little more color on that? Would that be partnering our assets? Would that be licensing, you know, patents? You know, how much of the IP estate or products are you looking to potentially partner? Thanks. Thanks, Raju, and short answer is all of the above. We're having a very broad IP portfolio ranging, you know, from allogeneic patents to NKG2D, shRNA. A lot of patents also developed internally, organically at Celyad. For those our wish is to have, you know, patients to be treated and partners of the industry to be able to benefit from this IP through licensing or any other mutually beneficial situation that we will come up with. Great. Thank you. Thank you. Ladies and gentlemen, as a reminder, if you'd like to join the question queue, please press star one on your telephone keypad. We'll pause a moment to allow for questions. Thank you. Our next question comes from line of Reid McCulloch with Wells Fargo. Please proceed with your question. Hi. Thank you for taking my question. This is Reid on for Nick. Can you provide any more color on the manufacturing that you're trying to proceed with and help expand here in the space? Thank you. Yes, Reid. Good afternoon, and I'd be happy to do that. Basically if you get back years ago when Celyad and even previously Cardio3 got engaged in cell therapy. It was very difficult for early stage companies not to have a GMP facility because it was not available. We took the major endeavor at that point to be fully integrated with a GMP facility that has been very helpful both when we were in the cardiac field and more recently in the CAR- T space. In the past we've come through periods where, because of timing of clinical studies, our resources were underutilized, and we have a history in the past of, for example, having other companies in the cell therapy to rent some of our space. Now we are entering in a phase where also we may have a, you know, we have an overcapacity in our manufacturing capacity, and so we have the chance to have other projects. What is the exact, you know, modus operandi of making this capacity available to others is under development right now. There are a number of ways that we can make this manufacturing unit as well as the QA and all of our great trained personnel to benefit to other technologies as well. Great. Thank you. My pleasure. Thank you. Ladies and gentlemen, this concludes our question and answer session. I'll turn the floor back to Mr. Lussier for any final comments. Thank you, operator, and I'd like to thank everyone for joining us today and your interest in Celyad Oncology. We remain steadfast in our mission to bring novel and innovative CAR- T therapies to cancer patients with unmet medical needs, and we're looking forward to speaking to you all again soon. Thank you. Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.